RxDoctor Payments Data

Amanda Pong

Neurology with Special Qualifications in Child Neurology · Stamford, CTNPI 1750583399

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,816 of the $9,602 with a category attached, or 81.4%. It is spread thinly across 37 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,944 and has fallen 63.0% since, to $1,458 in 2025.

$9,602in general payments, 2019–2025

Across 293 payments — averaging $32.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • H. Lundbeck A S$2K
  • Livanova USA, Inc.$862
  • SK Life Science, Inc.$636
  • Neurelis, Inc.$474
  • Jazz Pharmaceuticals Inc.$402
  • plus $4K from 31 others
$226,213in research payments, 2019–2025

Across 25 payments — averaging $9048.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • H. Lundbeck A S$226K

What the payments were for

  • Travel & lodging$1,76918%
  • Food & beverage$7,81681%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,602 in reported general payments places this provider in the 70th percentile of 28 neurology with special qualifications in child neurology providers in Connecticut.

See all neurology with special qualifications in child neurology providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide15$2,719

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →